

# ANTIMICROBIAL RESISTANCE

– *What a primary care physician needs to know*

Dr. Chandana Sarma MD,IDCCM

Senior Consultant ,Internal Medicine &Critical Care

Health City Hospital , Guwahati, Assam


# OBJECTIVES

- Magnitude of the problem of AMR.
- Major mechanisms of antimicrobial resistance.
- Methods of detection of AMR
- Identify the contributing factors
- Strategies to prevent AMR.

Disclosures-NONE

# Introduction

- In 1928 at St.Mary's Hospital ,London ,Sir Alexender Fleming discovered penicillin.
- This led to the introduction of antibiotics which has since shaped human history.
- However over the years unsustainable use of antimicrobials have led to growing resistance to them leading to an unprecedented global crisis.
- Antimicrobial resistance (AMR) is a **global health threat** that occurs when microbes like bacteria, viruses, fungi, and parasites evolve to become resistant to antimicrobials, making infections difficult to treat and raising the risk of severe illness and death.



# AMR-THE SILENT PANDEMIC

- Globally 700,000 deaths every year are attributable to AMR.
- If not contained 10,000,000 lives a year are estimated to be at risk by 2050, 90% of which will be in Asia and Africa.
- **1.27 million deaths** were directly attributable to resistance. **4.95 million deaths** were associated with bacterial AMR [Lancet 2022; 399: 629–55](#)
- Huge impact on Global economy. AMR was ranked as **5<sup>th</sup>** out of 10 threats to global health in **2019** by **WHO**.




Figure 2: All-age rate of deaths attributable to and associated with bacterial antimicrobial resistance by GBD region, 2019

**SOURCE**-LRTI, BSI and Intra abdominal infections accounted for **78·8%** of deaths attributable to AMR in 2019

**BUGS**-Together, six pathogens were responsible for **929000** of **1·27** million deaths attributable to AMR & **3·57 million** of **4·95** million deaths associated with AMR [Lancet 2022; 399: 629–55](#)




Figure 3: Global deaths (counts) attributable to and associated with bacterial antimicrobial resistance by infectious syndrome, 2019




Figure 4: Global deaths (counts) attributable to and associated with bacterial antimicrobial resistance by pathogen, 2019

# Overuse of antibiotics led to 60% of sepsis deaths in India: Lancet study

ANURADHA MASCARENHAS  
Pune, September 16

**WHEN A 60-YEAR-OLD** patient with leukaemia was admitted to the emergency department with high fever and low blood pressure, he was immediately started on broad-spectrum antibiotics. However, the drugs didn't work, complicating his condition. A blood culture later revealed a drug-resistant *Klebsiella* infection, which required a combination of drugs to bring it under control.

"The patient's condition deteriorated because of antimicrobial resistance (AMR), a condition where bacteria and parasites become resistant to medicines that were previously effective against them," said Dr Abdul Ghafur, infectious diseases expert at Apollo Hospital, Chennai.

Overuse or wrongful use of antibiotics is exacting a toll on

## IN NUMBERS

**2.9 million**

sepsis deaths in the country in 2019; 60% were due to wrongful use of antibiotics

**290,000**

sepsis deaths that year were directly attributable to bacterial antimicrobial resistance



**39 mn**

people around the world could die from antibiotic-resistant infections over next 25 years

**1 mn**

deaths were linked to bacterial AMR

the health of Indians, with a latest *Lancet* study showing that 60% of the 2.9 million sepsis deaths in the country in 2019 were caused by antimicrobial resistance. While about 290,000 sepsis deaths that year were directly attributable to bacterial AMR, nearly one million deaths were linked to it.

Sepsis deaths occur when one's immune system has a dan-

gerous reaction to a bacterial infection and without treatment, can lead to organ failure.

"AMR is the result of overuse of antibiotics earlier in the patient's lifetime or wrongful use. With rising rates of drug-resistant bacteria in India, treatment options are becoming increasingly limited, posing a public health challenge," said Dr Ghafur.

Already widely recognised as a major global health challenge, AMR is anticipated to worsen in the coming decades with *Lancet* predicting that more than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years. The report, based on a new study by the Global Research on Antimicrobial Resistance (GRAM) Project, is the first global analysis of antimicrobial resistance trends over time.

"Until now, no study has assessed historical trends of AMR and provided in-depth forecasts of future global impacts. Understanding how trends in AMR deaths have changed over time, and how they are likely to shift in future, is vital to make informed decisions to help save lives," said Dr Mohsen Naghavi, team leader of the AMR Research Team at the Institute of Health Metrics, University of Washington, US.

# *MECHANISM OF ANTIBIOTIC RESITANCE*

# *Basic concepts of antimicrobial resistance*


- **INTRINSIC RESISTANCE**-is inherent resistance to an antimicrobial that all or almost all members of a species display, rendering susceptibility testing unnecessary
- **AQUIRED RESISTANCE**: development of resistance to an antimicrobial to which members of the **wild-type** bacterial population are susceptible
- **Constitutively expressed resistance** mechanisms are expressed continuously.
- **Inducible expression occurs** following exposure to a particular inciting agent
- **Heteroresistance**-A phenomenon where subpopulations of seemingly isogenic bacteria exhibit a range of susceptibilities to a particular antibiotic.

## INTRINSIC RESISTANCE

<u>ANTIBIOTIC</u>	<u>BACTERIA</u>
Aztreonam	Gram positive bacteria
Aminoglycosides, Cephalosporins	Enterococci
Vancomycin	Gram negative bacteria
Sulphonamides, TMP, tetracyclines, chloramphenicol	P.aeruginosa
Ampicillin	Klebsiella spp
Imipenem	S.maltophilia
Aminoglycosides	Anaerobic bacteria
Metronidazole	Aerobic bacteria


# Mechanisms of antibiotic resistance

- Inactivating enzymes
- Modification of target site
- Replacement of target site
- Decreased uptake
- Efflux




# Inactivation by a bacterial enzyme


- Production of **beta-lactamases** is a major mechanism of resistance to the **beta-lactam antibiotics** in clinical isolates.



## $\beta$ -lactamases in *Enterobacterales*




## Modification of the antibiotic target site



The target sites for the beta-lactams are the **PBPs** in the cytoplasmic membrane.

Alterations in PBPs may influence their binding affinity for beta-lactam antibiotics and therefore the sensitivity of the altered bacterial cell to inhibition by these antibiotics. eg **Penicillin resistance in Streptococcus Pneumoniae**

## Replacement of the antibiotic target site




**PBP2a** is encoded by the **mecA gene**, which is carried on a mobile genetic element called SCC mec.

**PBP2a** has a lower affinity for beta-lactams, which allows the cell wall to continue to be built even when the antibiotic is present.

This is the mechanism by which **MRSA** is able to persist despite treatment with multiple beta-lactam antibiotics.

## Decreased penetration to the target site and efflux



Mutations that result in decreased amounts of **porin** channels, those that increase the amounts of native active **efflux** pumps, or both can contribute to acquired resistance to beta-lactams.


Found typically in pseudomonas and Acinetobacter, it inactivates ticarcillin, higher generations of cephalosporins, FQ, AG, Carbapenems, tigecycline etc

# Other mechanisms of Antibiotic resistance

- Topoisomerase modification and gyrase modifications-found in pseudomonas, Enterobacteriaceae, Acinetobacter .They inactivate fluroquinolones.
- Aminoglycoside modifying enzymes(AME)-Produced in Enterobacteriaceae, Acinetobacter, etc. They inactivae aminoglycosides.
- Methylation of 16 ribosomal subunit-found in enterobactereriaceae, inactivate Plazomycin
- Lipid A modification, mcr gene mutation and Pmr A and B modifications-Found in Klebsiella, Pseudomonas, Acinetobacter and Enterobacteriaceae. They Inactivate Polymixins.

# Genetic basis of AMR

- From an evolutionary perspective, bacteria use two major genetic strategies to adapt to the antibiotic.
- Spontaneously occurring **mutations** in gene(s) conferring resistance and **vertically** transmitted due to multiplication as its competitor is killed by the antibiotic.
- Acquisition of foreign DNA coding for resistance determinants through **horizontal gene transfer (HGT)**
- Classically, bacteria acquire external genetic material through three main strategies: (i) **transformation** (incorporation of naked DNA), (ii) **transduction** (phage mediated), and (iii) **conjugation** (bacterial “sex”).




# SPECTRUM OF RESISTANCE

I

- If the resistance is against only one type of antimicrobial (structurally and mechanistically similar), it is simply called **resistance to that particular class**.
- If resistant to at least “*one antimicrobial in three or more categories*” of structurally unrelated antimicrobials, then it is called “**multi-drug resistance (MDR)**.”
- MDR is further classified as “**Extensively Drug-Resistant (XDR)**”, and “**Pan Drug-Resistant (PDR)**”. XDR organisms will be susceptible to antimicrobials in at most two structurally unrelated antimicrobial classes. PDR organisms will be resistant to all available antimicrobials.

# Drug Resistant TB



## Multi-Drug Resistant TB (MDR-TB)

- Manifest resistance to both Isoniazid and Rifampicin
- Globally, around 3.4% of the new TB patients and 20% of patients with a history of preceding medication for TB were identified as MDR-TB

## Extensively-Drug Resistant TB (XDR-TB)


- MDR strains that offer additional resistance to any fluoroquinolone
- Plus at least one of the following: Linezolid or Bedaquiline

## Drug Resistance caused by

- Incorrect prescribing
- Irregular supply of drug
- Patient non-adherence
- Low-grade quality of drugs


# ANTI-VIRAL RESISTANCE

- Antiviral drug resistance is an increasing concern in immuno-compromised patient populations, where ongoing viral replication and prolonged drug exposure lead to the selection of resistant strains.
- Various modes of resistance in six exemplary viruses including RNA viruses **HCV**, influenza A virus (**IAV**), DNA viruses (**HSV**) and human cytomegalovirus (**HCMV**), retrovirus **HIV**, and unconventionally replicating **HBV** have been studied.
- Knowledge of genetic mechanisms and associated viral mutations has allowed for development of genotypic techniques for the timely diagnosis of resistance.




# ANTI FUNGAL RESISTANCE

- The frequent use of antifungal agents has led to the development of robust resistance in medically important fungi. Resistance to **azoles** and **echinocandins** is well documented, while resistance to **polyenes** remains rare.
- Antifungal resistance can develop through a number of mechanisms, including:
  - **Altering the drug target:**
  - **Reducing intracellular drug levels:**
  - **Decreased access to the drug target:** .
  - **Point mutations:** This can include mutations in the FKS1 gene.
  - **Activation of stress responses**



# DETECTING AMR

- **Phenotypic methods** These methods are cheaper and more reliable, but they involve culturing, subculturing, and plating steps, which can be time-consuming. Examples include- broth dilution, gradient diffusion, and disc diffusion.
- **Automated systems** include Vitek2 (BioMérieux), MicroScan WalkAway (Beckman Coulter), or Phoenix (Becton Dickinson).
- **Molecular methods** These methods can detect AMR genes in microbes. Examples include: **PCR**: A technique that can amplify target DNA sequences, **DNA microarray technology**: A method that can detect the presence or absence of genes, **Whole-genome sequencing (WGS)**: A method that can detect genetic determinants of AMR



# Health City HOSPITAL

Fully Accredited  
NABH Hospital

Fully Accredited  
NABH Blood Bank

## DEPARTMENT OF LABORATORY MEDICINE

Patient Name	: Mrs. TAPATI DEB	Lab No	: 1044021
UHID / IP No	: 178572 / 24/2626	Sample Date	: 28/11/2024 2:46PM
Age/ Gender	: 66 Yrs/Female	Receiving Date	: 28/11/2024 8:19PM
Bed No/Ward	: ICU 2(1617)	Report Date	: 01/12/2024 11:33 AM
Referred By	: Dr. Chandana Sarma	Report Status	: Final
Category	: North Frontier Railway (NFR)	Order No	: IP24/64860

### Microbiology

Result Stage :2, Final (12/1/2024 2:20:00 PM)

### BLOOD FOR CULTURE & SENSITIVITY AEROBIC

Specimen Type:	BLOOD
Method:	BACT ALERT 3D SYSTEM, Conventional Aerobic Culture, VITEK-2 ID and Sensitivity

### CULTURE & SENSITIVITY REPORTS

Organism 1		Klebsiella pneumoniae	
Antibiotic Name	Interpretation	MIC (ug/ml)	Break Points I S R
Amikacin	Resistant	32 mcg/ml	8 <=4 >=16
Amoxicillin/Clavulanic Acid	Resistant	>=32 mcg/ml	16 <=8 >=32
Cefepime	Resistant	>=32 mcg/ml	4-8 SCD <=2 >=16
Cefoperazone/Sulbactam	Resistant	>=64 mcg/ml	32 <=16 >=64
Ceftriaxone	Resistant	>=64 mcg/ml	2 <=1 >=4
Ceftriaxone /Sulbactam FUTA	Sensitive		
Cefuroxime	Resistant	>=64 mcg/ml	8-16 <=4 >=32
Cefuroxime Axetil	Resistant	>=64 mcg/ml	
Ciprofloxacin	Resistant	>=4 mcg/ml	0.5 <=0.2 5 >=1
Colistin	Intermediate	2 mcg/ml	<=2 >=4
Ertapenem	Resistant	>=8 mcg/ml	1 <=0.5 >=2
Gentamicin	Resistant	>=16 mcg/ml	4 <=2 >=8
Imipenem	Resistant	>=16 mcg/ml	2 <=1 >=4
Meropenem	Resistant	>=16 mcg/ml	2 <=1 >=4
Piperacillin/Tazobactam	Resistant	>=128 mcg/ml	16 SCD <=8 >=32
Tigecycline	Sensitive	2 mcg/ml	4 <=2 >=8
Trimethoprim/Sulfamethoxazole	Resistant	>=320 mcg/ml	<=40 >=80

*Handwritten Signature*

Dr. Melody Baruah  
MBBS, MD (18704-AMC)

Dr. Himadri Dutta  
MBBS, MD (Microbiology)(18931-AMC)

Dr. Jyotish Barman  
MBBS, DCP(GMC)(16319-AMC)


N.H. 37 | Koinadhar | Khanapara | Guwahati | 781022 | Assam | India  
Consultant Microbiologist

Ph: 0361-3521600 | 86389 95504 | 0361-7105000

Email : customer@healthcityhospital.com | Website : www.healthcityhospital.com



**WHAT ARE THE MAJOR  
CONTRIBUTING FACTORS OF AMR?**



***WHAT ARE THE SOLUTIONS ?***

# Restricted Antibiotics

The AWaRe Classification of antibiotics was developed in 2017 by the WHO Expert Committee

Antibiotics are classified into three groups - **Access, Watch and Reserve**

**A**

**Access**

This indicates the antibiotic of choice for each of the 25 most common infections. These antibiotics should be available at all times, affordable and quality-assured.

**Wa**

**Watch**

This includes most of the 'highest priority critically important antimicrobials' for human medicine and veterinary use. These antibiotics are recommended only for specific, limited indications.


**Re**

**Reserve**

These antibiotics should only be used as a last resort when all other antibiotics have failed.

# ANTIMICROBIAL STEWARDSHIP

- **ANTIMICROBIAL STEWARDSHIP** is a set of actions and commitments to improve how antibiotics are used and prescribed, with the goal of improving patient safety and reducing adverse events. It involves ensuring that antibiotics are only used when necessary and appropriate.
- **ANTIBIOGRAM**- The hospital antibiogram is a periodic summary of antimicrobial susceptibilities of local bacterial isolates to aid in selecting empiric antibiotic therapy, to monitor resistance trends over time within an institution and compare susceptibility rates across institutions and track resistance trends.
- **ANTIBIOTIC POLICY** -Generally, the hospital antibiotic policy should concur or align with the national antibiotic policy except for a few changes as warranted by the local antimicrobial resistance profiles



# Rational antibiotics

	Type 1 (CAI)	Type 2 (HCAI)	Type 3 (NI)
<b>Health Care Contact(last 90days)</b>	No	Yes	Prolonged
<b>Procedures</b>	No	Minimum	Major invasive Procedures
<b>Antibiotic Rx History</b>	No in last 90 days	Yes in last 90 days	Repeat multiple antibiotics.
<b>Patients Characteristics</b>	Young – No co-morbid conditions.	Elderly Few Co-morbid conditions.	Immunocompromised, or with many co-morbid conditions.
<b>Causative Pathogen could be</b>	<b>Susceptible to Common narrow spectrum antibiotics</b>	<b>ESBLs</b>	<b>ESBLs / Pseudomonas /Acinetobacter MRSA</b>
<b>Possible Antibiotic recommendations</b>	<b>- No Need for Broad spectrum antibiotics</b>	<b>- Use Non-Pseudomonal broad spectrum antibiotics</b>	<b>- Use Anti-pseudomonal Broad spectrum antibiotics</b>

Ref: Based on stratification criteria suggested by Dr Yehuda Carmelli

# Antibiotics for surgical prophylaxis


- Antibiotics should be given **1 hour** before proceeding with incision (at induction of anesthesia).
- Second dose may be given ... if surgery prolongs **> 4 hours** - readministered every 4 hours (exception - vancomycin, aminoglycosides, and fluroquinolones).
- Prophylactic antibiotic should be **discontinued within 24hours** of the end of surgery.

IDSA guidelines - 2013

# Conclusion

- AMR is due to unsustainable practices and overlapping ecosystems of animal , environmental and human health.
- Reduce the misuse and overuse of antibiotics in livestock, aquaculture and crops.
- Effective management of waste from food systems, pharmaceutical manufacturing and health care systems .
- **Antibiotic stewardship** is important for preserving existing antibiotics and improving patient outcomes.
- Vaccination can reduce the use of antimicrobials.
- It needs guidance from **policymakers** and strong will from all **clinicians** to achieve control over misuse of antibiotic and reduce development of resistance.

DO YOU KNOW?  
MEDICINES WITH A **RED LINE** ON  
THE STRIP SHOULD NEVER BE CONSUMED  
WITHOUT DOCTOR'S PRESCRIPTION



THANK YOU

**LOOK OUT FOR THE RED LINE**  
**BE RESPONSIBLE**

Medicines such as Antibiotics have a **red vertical line** on their packs to indicate that these should be consumed only on doctor's advice. Always complete the full course as prescribed by the doctor.